Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
MOUNTAIN VIEW, Calif., Feb. 29, 2016 -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's fourth quarter 2015 financial results will be released after market close on Monday, March 14, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2016, to discuss these results and to answer questions.
To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 58052541. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing reduction and elimination of high-dose steroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. CCX168 is also in Phase II studies for the treatment of atypical hemolytic uremic syndrome (aHUS) and immunoglobulin A nephropathy, or IgA nephropathy (IgAN). CCX872, a CCR2 inhibitor, successfully completed Phase I development and is in development for the treatment of non-resectable pancreatic cancer. CCX140, a distinct CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvement in albuminuria in patients with diabetic nephropathy. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development, vercirnon (also known as Traficet-EN or CCX282) a specific CCR9 inhibitor for the treatment of inflammatory bowel disease, and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.
CCXI-G
Contacts: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer [email protected] Media: Denise Powell 510.703.9491 [email protected] Investors: Steve Klass Burns McClellan 212.213.0006 [email protected]
